Interstitial Pulmonary Fibrosis (IPF) Bleomycin-Induced Lung Fibrosis

Discovery

In rodents, a single intratracheal administration of Bleomycin leads to a well characterised response of 7-10 days of neutrophilic inflammation followed by a fibrotic response from around day 10 following bleomycin administration.

Currently there are only 2 approved drugs, that have been shown to slow the progression of Interstitial Pulmonary Fibrosis (IPF), nintedanib and pirfenidone.

Significant decreases in PV loops following bleomycin administration (Day 0) at Day 21, partially attenuated by therapeutic Pirfenidone Treatment

Study Design
Species/Strain	SD rat, C57BL/6J mouse
Model	Bleomycin induced fibrosis (single intratracheal administration)
Relevant Use	Assessing the efficacy of new compounds to slow the progression of IPF
Readouts Available	Daily Bodyweights and Clinical Signs, Lung Function (Resistance, Compliance, PV Loops), BAL differential cell counts, Bal TGF-β, BAL cytokines, Lung Hydroxyproline, Ashcroft Scoring and Pathology

Study data generated by Labcorp Huntingdon Pharmacology.

Molecule or Product Type

Biologics, Small Molecule

Models

Mouse, Rat

Administration Routes

Dermal, Dietary, Gavage, Implant, Infusion, Inhalation, Intracranial, Intracutaneous, Intramuscular, Intranasal, Intraperitoneal, Intrathecal, Intratracheal, Intravenous, Ocular, Rectal, Subcutaneous, Transcortical, Vaginal

Regulatory

IND & CTA, NDA & BLA, Post-Market

Industry Market

Pharma

Phase

Discovery, Nonclinical

Related Models

Request a Quote

About our nonclinical animal research models: We provide the utmost care for our research animals and actively pursue advances in animal welfare. As well as ensuring the highest scientific, ethical and regulatory standards, selection of appropriate animal research models for development research is critical to developing safe and effective treatments, devices and products that protect and save lives. Just as we have ethical committee oversight for human trials, we have ethical committees overseeing all aspects of our global animal care and use programs. All of our core, nonclinical facilities are accredited by AAALAC. Learn more about our commitment to replacing, reusing and refining nonclinical research models.